# Cizzle Biotechnology begins US commercial launch of lung cancer blood test

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-begins-us-commercial-launch-of-lung-cancer-blood-test/4121259382
- Published: 2026-08-05T13:06:00+01:00
- Author: Amilia Stone

Cizzle Biotechnology has started the commercial rollout of its CIZ1B lung cancer
blood test in the United States, moving the technology from laboratory validation
into clinical availability.

The test is being introduced through Cizzle Bio, the company’s North American licensing
partner, and will initially be available to licensed healthcare providers in the
Dallas-Fort Worth and San Antonio areas of Texas.

This is the first commercial launch of the CIZ1B test in the US and marks a clear
change in Cizzle Biotechnology’s development profile. The company is now beginning
the process of building clinical use, establishing demand and supporting a wider
commercial network.

Cizzle Bio holds exclusive rights to commercialise the test in the United States,
Canada and the Caribbean. The Texas launch provides a controlled starting point 
in a large healthcare market, allowing the partners to assess how the test is used
by physicians before expanding into additional regions.

The test has completed laboratory validation at OmniHealth Diagnostics, a Dallas-
based laboratory operating under Clinical Laboratory Improvement Amendments certification.
OmniHealth will process blood samples and issue results, providing the laboratory
infrastructure required for the first stage of commercial delivery.

CIZ1B is designed to detect a protein variant associated with early-stage lung cancer
from a standard blood sample. It is intended to support existing diagnostic methods
rather than replace them. The test may be used alongside low-dose computed tomography
scans and other clinical assessments, particularly where a patient has a suspicious
scan result or requires further risk evaluation.

_**Cizzle Biotechnology Holdings plc** (LON:CIZ) is a pioneering cancer diagnostics
company, originally a spin-out from the University of York, and now listed on the
London Stock Exchange._

Share on: